Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems

Raschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., Moretti, U.·2018·Nutrition, Metabolism and Cardiovascular Diseases
DOI 10.1016/j.numecd.2018.02.014

Cited by (119)

Items 101–119 of 119

  1. Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo · 2025 · Future Journal of Pharmaceutical Sciences
  2. Pharmacovigilance
    Charmy S. Kothari, Manan Shah, Rajvi Manthan Patel · 2019 · IntechOpen eBooks
  3. Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
    Emanuel Raschi, Michele Fusaroli, Igor Diemberger, Elisabetta Poluzzi · 2021 · Drug Safety
  4. Estudio de eventos adversos asociados al consumo de diferentes antidiabéticos en Colombia entre 2013 – 2018
    Arley Pino Muñoz · 2019
  5. Катакомбное наследство: реальность или миф
    М. З. Омаров · 2007 · CyberLeninK (CyberLeninka)
  6. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Induced Neurocognitive Disorder: A Pharmacovigilance Study by Analyzing the Data from the U.S. FDA Adverse Event Reporting System
    Yang Hu, Ziyu Bai, Tianxin Huang, Xinyue Zhang, Qianqian Fan, Bin Zhao, Zhuang Tian · 2021 · Research Square
  7. Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ?
    André Jacques Scheen · 2022 · Médecine des Maladies Métaboliques
  8. Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”
    Tianqi Gu, Anqi Lin, Haitao Wang, Jian Zhang, Peng Luo · 2023 · International Journal of Cancer
  9. Author’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”
    John‐Michael Gamble, Wajd Alkabbani · 2023 · Drug Safety
  10. Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system
    Ling Liu, Chengyi Zhang, Huihui Liu, Huan Luo, Rong Cao, Mingxuan Xiao, Pan Zou, Zhuzhu Xie, Hui Gong, Rui Ma et al. · 2024 · Expert Opinion on Drug Safety
  11. Association between voriconazole-induced visual hallucination and dopamine: an analysis of the food and drug administration adverse event reporting system database
    Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto · 2024 · Research Square
  12. Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
    Kaidi Zhao, Xuanfeng Tan, Miao Qin, Qing Li, Qinqin Meng, Ying Liu, Jing Li, Jiashu Liu · 2025 · Frontiers in Medicine
  13. Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study
    Bo Xu, Tianqiao Zhang, Yun He, Aihua Jiang, Yinglan Liu, Zunbo He, Jiecan Zhou · 2025 · Expert Opinion on Drug Safety
  14. Additional file 2 of Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®
    Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Ceschi, Alessandro, Zecca, Chiara · 2024 · Figshare
  15. Additional file 1 of SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
    Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Fadini, Gian Paolo · 2021 · Figshare
  16. Additional file 3 of Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®
    Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Ceschi, Alessandro, Zecca, Chiara · 2024 · Figshare
  17. Additional file 1 of Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®
    Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Ceschi, Alessandro, Zecca, Chiara · 2024 · Figshare
  18. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology
    Xiaoxuan Xing, Ke Wang, Yingnan Feng, Chao Wu, Lihua Jia, Huiying Li, Zhiyong Wen, Yinan Tang, Zi Wang, Xiaotong Zhang et al. · 2026 · Frontiers in Psychiatry
  19. Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study
    S S Zhao, Lu-Yao Xu, Ping Chen, Su Zhang, Kai-Li Mao · 2026 · Frontiers in Oncology